{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:34:42Z","timestamp":1793093682544,"version":"4.5.0"},"reference-count":62,"publisher":"American Chemical Society (ACS)","issue":"14","license":[{"start":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T00:00:00Z","timestamp":1468022400000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_termsofuse.html"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The clinical management of prosthetic joint infections and other persistent bacterial infections represents a major unmet medical need. The rifamycins are one of the most potent antibiotic classes against persistent bacterial infections, but bacteria can develop resistance to rifamycins rapidly and the clinical utility of the rifamycin class is typically limited to antibiotic combinations to minimize the development of resistance. To develop a better therapy against persistent bacterial infections, a series of rifamycin based bifunctional molecules were designed, synthesized, and evaluated with the goal to identify a dual-acting drug that maintains the potent activity of rifamycins against persistent pathogens and at the same time minimize the development of rifamycin resistance. TNP-2092 was identified as a drug candidate and is currently in an early stage of clinical development for the treatment of prosthetic joint infections.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6b00485","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T17:31:33Z","timestamp":1466703093000},"page":"6645-6657","source":"Crossref","is-referenced-by-count":83,"title":["Development of\na Dual-Acting Antibacterial Agent (TNP-2092)\nfor the Treatment of Persistent Bacterial Infections"],"prefix":"10.1021","volume":"59","author":[{"given":"Zhenkun","family":"Ma","sequence":"first","affiliation":[{"name":"TenNor Therapeutics Ltd. , 218 Xinghu Street, Suzhou Industrial Park , ,","place":["Suzhou, China, 215123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Simon","family":"Lynch","sequence":"additional","affiliation":[{"name":"Janssen Research & Development LLC. , 1400 McKean Road , , ,","place":["Spring House, Pennsylvania, United States, 18940"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2016,6,23]]},"reference":[{"issue":"10016","key":"2026090305360478000_cit1","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S0140-6736(14)61798-0","article-title":"Periprosthetic joint infection","volume":"387","author":"Kapadia","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"2026090305360478000_cit2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1128\/CMR.00111-13","article-title":"Prosthetic joint infection","volume":"27","author":"Tande","year":"2014","journal-title":"Clin. Microbiol.\nRev."},{"issue":"1","key":"2026090305360478000_cit3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/cis966","article-title":"Executive\nsummary: Diagnosis and management of prosthetic joint infection: Clinical\npractice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"2026090305360478000_cit4a","doi-asserted-by":"publisher","first-page":"987","DOI":"10.2217\/fmb.14.64","article-title":"Biofilms in periprosthetic orthopedic\ninfections","volume":"9","author":"McConoughey","year":"2014","journal-title":"Future Microbiol."},{"issue":"2","key":"2026090305360478000_cit4b","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/17453674.2014.966290","article-title":"The role of microbial\nbiofilms in prosthetic joint infections","volume":"86","author":"Gbejuade","year":"2015","journal-title":"Acta\nOrthop."},{"key":"2026090305360478000_cit5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0065-7743(04)39016-0","article-title":"Therapeutic\nopportunities for the treatment of biofilm-associated infections","volume-title":"Annual Reports in Medicinal Chemistry","author":"Ma","year":"2004"},{"issue":"5","key":"2026090305360478000_cit6a","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s11908-008-0064-1","article-title":"Diagnosis and treatment\nof implant-associated\nseptic arthritis and osteomyelitis","volume":"10","author":"Trampuz","year":"2008","journal-title":"Current\ninfectious disease reports"},{"issue":"12","key":"2026090305360478000_cit6b","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/1469-0691.12003","article-title":"Antimicrobial treatment concepts\nfor orthopaedic device-related infection","volume":"18","author":"Sendi","year":"2012","journal-title":"Clin.\nMicrobiol. Infect."},{"issue":"4","key":"2026090305360478000_cit6c","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3109\/17453674.2015.1026756","article-title":"75% success\nrate after open debridement, exchange of tibial insert, and antibiotics\nin knee prosthetic joint infections","volume":"86","author":"Holmberg","year":"2015","journal-title":"Acta Orthop."},{"issue":"Suppl. 3","key":"2026090305360478000_cit7","doi-asserted-by":"publisher","first-page":"S402","DOI":"10.1093\/clinids\/5.Supplement_3.S402","article-title":"History of\nthe development of rifampin","volume":"5","author":"Sensi","year":"1983","journal-title":"Clin. Infect. Dis."},{"key":"2026090305360478000_cit8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/B0-08-045044-X\/00224-8","article-title":"Antimycobacterium\nagents","volume-title":"Comprehensive Medicinal Chemistry\nII","author":"Ma","year":"2007"},{"issue":"8","key":"2026090305360478000_cit9","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.mayocp.2015.04.016","article-title":"Therapeutic\neffects and mechanisms of action of rifaximin in gastrointestinal\ndiseases","volume":"90","author":"DuPont","year":"2015","journal-title":"Mayo Clin. Proc."},{"issue":"6","key":"2026090305360478000_cit10","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","article-title":"Structural\nmechanism for rifampicin\ninhibition of bacterial RNA polymerase","volume":"104","author":"Campbell","year":"2001","journal-title":"Cell"},{"issue":"9","key":"2026090305360478000_cit11a","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/ja.2014.107","article-title":"Resistance to rifampicin: a review","volume":"67","author":"Goldstein","year":"2014","journal-title":"J. Antibiot."},{"issue":"4","key":"2026090305360478000_cit11b","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1128\/AAC.48.4.1289-1294.2004","article-title":"Effect\nof rpoB mutations conferring rifampin resistance on fitness of Mycobacterium\ntuberculosis","volume":"48","author":"Mariam","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"2026090305360478000_cit12","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1038\/emi.2014.17","article-title":"The impact of drug resistance on\nMycobacterium tuberculosis physiology: what can we learn from rifampicin?","volume":"3","author":"Koch","year":"2014","journal-title":"Emerging Microbes Infect."},{"key":"2026090305360478000_cit13a","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/1471-2334-14-140","article-title":"Oral antibiotic therapy for the treatment of infective\nendocarditis: a systematic review","volume":"14","author":"Al-Omari","year":"2014","journal-title":"BMC Infect.\nDis."},{"issue":"1","key":"2026090305360478000_cit13b","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jbspin.2012.09.008","article-title":"Optimizing\ncombination rifampin therapy for staphylococcal osteoarticular infections","volume":"80","author":"Coiffier","year":"2013","journal-title":"Jt., Bone, Spine"},{"issue":"1","key":"2026090305360478000_cit13c","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1128\/CMR.00034-09","article-title":"Rifampin combination therapy for\nnonmycobacterial infections","volume":"23","author":"Forrest","year":"2010","journal-title":"Clin Microbiol\nRev."},{"issue":"9","key":"2026090305360478000_cit14a","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1007\/s11999-015-4300-3","article-title":"Rifamycin\nderivatives are effective against staphylococcal biofilms in vitro\nand elutable from PMMA","volume":"473","author":"Sanchez","year":"2015","journal-title":"Clin. Orthop. Relat.\nRes."},{"issue":"1","key":"2026090305360478000_cit14b","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40121-014-0055-5","article-title":"Evaluation of high-dose daptomycin versus vancomycin\nalone or combined with clarithromycin or rifampin against Staphylococcus\naureus and S. epidermidis in a novel in vitro PK\/PD model of bacterial\nbiofilm","volume":"4","author":"Hall Snyder","year":"2015","journal-title":"Infect. Dis. Ther."},{"issue":"5","key":"2026090305360478000_cit14c","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1128\/AAC.02420-12","article-title":"High activity of fosfomycin\nand rifampin against methicillin-resistant staphylococcus aureus biofilm\nin vitro and in an experimental foreign-body infection model","volume":"58","author":"Mihailescu","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl.\n1","key":"2026090305360478000_cit15","doi-asserted-by":"publisher","first-page":"i29","DOI":"10.1093\/jac\/dku253","article-title":"Clinical\nguidelines in the management\nof prosthetic joint infection","volume":"69","author":"Minassian","year":"2014","journal-title":"J. Antimicrob.\nChemother."},{"issue":"6","key":"2026090305360478000_cit16a","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/clinids\/14.6.1251","article-title":"Antimicrobial\ntreatment of orthopedic implant-related\ninfections with rifampin combinations","volume":"14","author":"Widmer","year":"1992","journal-title":"Clin.\nInfect. Dis."},{"issue":"19","key":"2026090305360478000_cit16b","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","article-title":"Role of rifampin for treatment of orthopedic implant-related\nstaphylococcal infections: A randomized controlled trial. Foreign-Body\nInfection (FBI) Study Group","volume":"279","author":"Zimmerli","year":"1998","journal-title":"JAMA"},{"issue":"8","key":"2026090305360478000_cit16c","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2165\/00003495-200666080-00005","article-title":"Antimicrobial\nagents in orthopaedic surgery: Prophylaxis and treatment","volume":"66","author":"Trampuz","year":"2006","journal-title":"Drugs"},{"issue":"3","key":"2026090305360478000_cit17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jmii.2015.06.006","article-title":"RNA polymerase B\nsubunit gene mutations in biofilm-embedded\nmethicillin-resistant Staphylococcus aureus following rifampin treatment","volume":"49","author":"Tang","year":"2016","journal-title":"J. Microbiol., Immunol. Infect."},{"issue":"6","key":"2026090305360478000_cit18a","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/AAC.41.6.1293","article-title":"In vitro activities of ciprofloxacin and rifampin alone\nand in combination against growing and nongrowing strains of methicillin-susceptible\nand methicillin-resistant Staphylococcus aureus","volume":"41","author":"Bahl","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"2026090305360478000_cit18b","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1128\/AAC.00458-08","article-title":"Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin\nin staphylococcal experimental foreign-body infection","volume":"52","author":"Murillo","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"2026090305360478000_cit18c","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1128\/AAC.06383-11","article-title":"Effect of coadministration\nof moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine\naerosol infection model","volume":"56","author":"Balasubramanian","year":"2012","journal-title":"Antimicrob. Agents\nChemother."},{"issue":"13","key":"2026090305360478000_cit19a","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.2174\/092986707780831168","article-title":"Dual action-based\napproaches to antibacterial agents","volume":"14","author":"Bremner","year":"2007","journal-title":"Curr. Med.\nChem."},{"issue":"9","key":"2026090305360478000_cit19b","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1517\/17460441.2010.508069","article-title":"Dual-acting hybrid antibiotics: a\npromising strategy to combat bacterial resistance","volume":"5","author":"Pokrovskaya","year":"2010","journal-title":"Expert Opin. Drug Discovery"},{"issue":"1","key":"2026090305360478000_cit19c","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1070\/RCR4448","article-title":"Design of dual action antibiotics as an approach to\nsearch for new promising drugs","volume":"84","author":"Tevyashova","year":"2015","journal-title":"Russ. Chem.\nRev."},{"key":"2026090305360478000_cit19d","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0065-7743(08)00017-1","article-title":"Recent advances\nin the discovery of hybrid antibacterial agents","volume-title":"Annual Reports in Medicinal Chemistry","author":"Barbachyn","year":"2008"},{"issue":"7","key":"2026090305360478000_cit20a","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1128\/AAC.33.7.1067","article-title":"Mode of\naction of the dual-action cephalosporin Ro\n23-9424","volume":"33","author":"Georgopapadakou","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"2026090305360478000_cit20b","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1128\/AAC.34.10.1895","article-title":"Pharmacokinetics of Ro 23-9424, a\ndual-action cephalosporin, in animals","volume":"34","author":"Christenson","year":"1990","journal-title":"Antimicrob.\nAgents Chemother."},{"issue":"2","key":"2026090305360478000_cit21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1128\/AAC.34.2.189","article-title":"In vitro activity\nof Ro 23-9424, a dual-action cephalosporin,\ncompared with activities of other antibiotics","volume":"34","author":"Gu","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"2026090305360478000_cit22","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1128\/AAC.01831-13","article-title":"Investigations\nof the mode of action and resistance development of cadazolid, a new\nantibiotic for treatment of Clostridium difficile infections","volume":"58","author":"Locher","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090305360478000_cit23","unstructured":"Ding, C. Z.; Ma, Z.; Li, J.; Harran, S.; He, Y.; Minor, K. P.; Kim, I. H.; Longgood, J. C.; Jin, Y.; Combrink, K. D., (R\/S) rifamycin derivatives, their\npreparations\nand pharmaceutical compositions. U.S. Patent 7,226,931, 2007."},{"issue":"5","key":"2026090305360478000_cit24a","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.bmcl.2006.12.026","article-title":"Synthesis and antibacterial\nevaluation of a novel series of rifabutin-like spirorifamycins","volume":"17","author":"Kim","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090305360478000_cit24b","unstructured":"(b)\n          \n            \n              Ma, Z.; Kim, I. H.; Li, J.\n          Spiro-rifamycin derivatives\ntargeting RNA polymerase. U.S. Patent 7,202,246, 2007."},{"key":"2026090305360478000_cit24c","unstructured":"(c)\n          \n            \n              Ding, C. Z.; Kim, I. H.; Wang, J.; Ma, Z.; Jin, Y.; Combrink, K. D.; Lu, G.; Lynch, A. S.\n          Nitroheteroaryl-containing rifamycin\nderivatives. U.S. Patent 7,678,791, 2010."},{"issue":"20","key":"2026090305360478000_cit25a","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1016\/j.bmcl.2007.08.048","article-title":"Preparation and in vitro anti-staphylococcal\nactivity of novel 11-deoxy-11-hydroxyiminorifamycins","volume":"17","author":"Li","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090305360478000_cit25b","unstructured":"(b)\n          \n            \n              Li, J.; Ding, C. Z.; Ma, Z.\n          Rifamycin C-11 oxime derivatives\neffective against drug-resistant microbes. U.S. Patent 7,265,107, 2007."},{"key":"2026090305360478000_cit25c","unstructured":"(c)\n          \n            \n              Li, J.; Ma, Z., Rifamycin C-11\noxime cyclo derivatives effective against drug-resistant microbes. U.S. Patent 7,256,187, 2007."},{"issue":"2","key":"2026090305360478000_cit26a","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.bmcl.2006.10.016","article-title":"New C25 carbamate rifamycin derivatives are resistant\nto inactivation by ADP-ribosyl transferases","volume":"17","author":"Combrink","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090305360478000_cit26b","unstructured":"(b)\n          \n            \n              Combrink, K.; Harran, S.; Denton, D.; Ma, Z.\n          C-25 carbamate\nrifamycin derivatives with activity against drug-resistant microbes. U.S. Patent 7,250,413, 2007."},{"key":"2026090305360478000_cit27","unstructured":"Ding, C. Z.; Jin, Y.; Combrink, K.; Kim, I. H.\n          Quinolone carboxylic\nacid-substituted rifamycin derivatives. U.S. Patent 7,884,099, 2011."},{"key":"2026090305360478000_cit28","unstructured":"Ma, Z.; Jin, Y.; Li, J.; Ding, C. Z.; Minor, K. P.; Longgood, J. C.; Kim, I. H.; Harran, S.; Combrink, K.; Morris, T. W.\n          Rifamycin derivatives\neffective against\ndrug-resistant microbes. U.S. Patent 7,247,634, 2007."},{"issue":"4","key":"2026090305360478000_cit29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/1098-1128(200007)20:4&lt;231::AID-MED1&gt;3.0.CO;2-N","article-title":"The 2-pyridone\nantibacterial agents:\nbacterial topoisomerase inhibitors","volume":"20","author":"Li","year":"2000","journal-title":"Med. Res.\nRev."},{"issue":"7","key":"2026090305360478000_cit30a","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1128\/AAC.43.7.1574","article-title":"DNA cleavage activities of Staphylococcus\naureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones","volume":"43","author":"Saiki","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"2026090305360478000_cit30b","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1093\/jac\/38.4.641","article-title":"Efficacy\nof ABT-719, a 2-pyridone antimicrobial, against enterococci, Escherichia\ncoli, and Pseudomonas aeruginosa in experimental murine pyelonephritis","volume":"38","author":"Meulbroek","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"2026090305360478000_cit31a","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1128\/AAC.01649-07","article-title":"In vitro evaluation\nof CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies\nof the mode of action in Staphylococcus aureus","volume":"52","author":"Robertson","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"2026090305360478000_cit31b","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1128\/AAC.01651-07","article-title":"In vitro evaluation of CBR-2092, a novel rifamycin-quinolone\nhybrid antibiotic: microbiology profiling studies with staphylococci\nand streptococci","volume":"52","author":"Robertson","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090305360478000_cit32a","unstructured":"(a)\n          \n            \n              Lynch, A. S.; Bonventre, E. J.; Doyle, T. B.; Du, Q.; Duncan, L.; Robertson, G. T.; Roche, E. D.\n          In vitro mode-of-action studies\nof CBR-2092: a novel rifamycin-quinolone hybrid antibiotic. Presented at the Interscience Conference on Antimicrobial Agents\nand Chemotherapy, 2007; ICAAC Poster F1-2101."},{"key":"2026090305360478000_cit32b","unstructured":"(b)\n          \n            \n              Robertson, G. T.; Bonventre, E. J.; Doyle, T. B.; Du, Q.; Duncan, L.; Roche, E. D.; Lynch, A. S., Comparative in vitro activity\nof CBR-2092, a novel rifamycin-quinolone hybrid antibiotic, and rifampin+quinolone\ncombinations. Presented at the Interscience Conference\non Antimicrobial Agents and Chemotherapy, 2007; ICAAC\nPoster F1-2102."},{"key":"2026090305360478000_cit32c","unstructured":"(c)\n          \n            \n              Du, Q.; Doyle, T. B.; Duncan, L.; Robertson, G. T.; Lynch, A. S., In vitro microbiology profiling\nof CBR-2092, a novel rifamycin-quinolone hybrid antibiotic. Presented at the Interscience Conference on Antimicrobial Agents\nand Chemotherapy, 2007; ICAAC Poster F1-2103."},{"key":"2026090305360478000_cit32d","unstructured":"(d)\n          \n            \n              Doyle, T. B.; Bonventre, E. J.; Du, Q.; Robertson, G. T.; Roche, E. D.; Lynch, A. S., In vitro studies of the efficacy\nof CBR-2092, a novel rifamycin-quinolone hybrid antibiotic, in killing\nstaphylococcal cells in biofilms. Presented at the\nInterscience Conference on Antimicrobial Agents and Chemotherapy, 2007; ICAAC Poster F1-2104."},{"key":"2026090305360478000_cit32e","unstructured":"(e)\n          \n            \n              Renick, P. J.; Morris, T. W.; Nguyen, P. M.; Pulse, M. E.; Weiss, W. J.\n          Efficacy of CBR-2092, a novel rifamycin-quinolone\nyybrid antibiotic, in rodent models of bacterial infection. Presented at the Interscience Conference on Antimicrobial Agents\nand Chemotherapy, 2007; ICAAC Poster F1-2105."},{"key":"2026090305360478000_cit32f","unstructured":"(f)\n          \n            \n              Weiss, W. J.; Bao, D.; Miller, G. A.; Morris, T. W.; Nguyen, P. M.; Pulse, M. E.; Renick, P. J.; Truong, T.\n          Pharmacokinetic\nand pharmacodynamic studies with CBR-2092, a novel rifamycin-quinolone\nhybrid antibiotic. Presented at the Interscience Conference\non Antimicrobial Agents and Chemotherapy, 2007; ICAAC\nPoster F1-2106."},{"key":"2026090305360478000_cit32g","unstructured":"(g)\n          \n            \n              Xiong, Y. Q.; Weiss, W. J.; Doyle, T. B.; Abdelsayed, G. A.; Bayer, A. S.\n          Efficacy of\nCBR-2092, a novel rifamycin-quinolone hybrid antibiotic, and vancomycin\nin experimental methicillin-resistant Staphylococcus aureus infective\nendocarditis. Presented at the Interscience Conference\non Antimicrobial Agents and Chemotherapy, 2007; ICAAC\nPoster F1-2107."},{"key":"2026090305360478000_cit32h","unstructured":"(h)\n          \n            \n              Xiong, Y. Q.; Weiss, W. J.; Doyle, T. B.; Abdelsayed, G. A.; Bayer, A. S.\n          Comparative\nefficacy of CBR-2092 and conventional rifampin+quinolone combinations\nin experimental infective endocarditis caused by a quinolone-resistant\nMRSA. Presented at the Interscience Conference on\nAntimicrobial Agents and Chemotherapy, 2007; ICAAC Poster\nF1-2108."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6b00485","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/59\/14\/6645\/67199317\/acs.jmedchem.6b00485.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/59\/14\/6645\/67199317\/acs.jmedchem.6b00485.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:36:13Z","timestamp":1788428173000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/59\/14\/6645\/1339702\/Development-of-a-Dual-Acting-Antibacterial-Agent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,23]]},"references-count":62,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2016,6,23]]},"published-print":{"date-parts":[[2016,7,28]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00485","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726443578.793521804","asserted-by":"object"}]},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,23]]}}}